Ypsomed strengthens its position in the diabetes sector by making a strategic acquisition of ICU Medical, Inc.'s Orbit(TM) diabetes infusion set business
ICU Medical, Inc. was one of the few independent manufacturers of diabetes infusion sets operating in the fiercely competitive and patent-protected market for insulin pump accessories. Through this acquisition Ypsomed secures ownership of ICU's diabetes infusion set patents. Until now, Ypsomed has been acting as trading partner for ICU Medical, Inc., selling its Orbit(TM) infusion set under the name of mylife(TM) Roto(TM) . This infusion set is distinguished by a 360-degree connector for easy rotation, a smooth low profile dome shape so patients' clothes do not snag, and an easy one handed activation.
The potential benefits of the acquisition for the business activities of the Burgdorf-based diabetes specialist are two-fold: Ypsomed intends to increase margins by making manufacturing more cost-effective and to further consolidate its position in the attractive infusion set market. Simon Michel, a member of the Ypsomed Group management and head of Marketing & Sales, is convinced that "the infusion set market for insulin pumps is already worth more than one billion dollars. With the Roto(TM) products, Ypsomed will be able to claim a share of this market in future." This strategic move also enables Ypsomed to ensure the availability of a key component for the launch of its own cost-effective and user-friendly insulin pump.
About ICU Medical, Inc.
ICU Medical, Inc develops, manufactures and sells innovative medical technologies used in vascular therapy, oncology and critical care applications. ICU Medical, Inc.'s products improve patient outcomes by helping prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company's complete product line includes custom I.V. systems, closed delivery systems for hazardous drugs, needleless I.V. connectors, catheters and cardiac monitoring systems. ICU Medical, Inc. is headquartered in San Clemente, California.
The Ypsomed Group is the leading independent developer and manufacturer of injection systems for self-medication and a recognised diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the well-known Disetronic Group, today offers insulin pumps, injection systems and pen needles for diabetes, growth hormone and infertility treatments as well as for other therapeutic fields. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland as well as specialist diabetes marketing companies throughout Europe. The Ypsomed Group employs a staff of approximately 1,050.